Many diagnostic firms saw gains in their stock prices last month as Invitae and NantHealth also saw healthy increases.
The 360Dx Index was up 12 percent last month as shares of Accelerate Diagnostics, Veracyte, and Exact Sciences each improved more than 40 percent month over month.
The firm lowered topline and non-GAAP earnings per share guidance for fiscal 2019.
OraSure CEO Stephen Tang discussed the firm's plans for international expansion, while Meridian CEO Jack Kenny said the firm needs to develop a new MDx platform.
The company's CEO noted softness in both its diagnostics and life science segment. The projected revenues would fall short of the consensus Wall Street estimate.
November's modest gain followed a tough October, when the index down almost 9 percent. Meridian Bio paced the gainers, and NantHealth was the steepest decliner.
The molecular test detects a form of herpes virus that can infect newborns and cause deafness.
In the firm's first-ever earnings call, new CEO Jack Kenny said the firm will invest more in R&D to revamp its aging portfolio.
The firm saw strong growth in respiratory illness assays and lead testing, which was offset by a decline in C. difficile testing.
DiaSorin will sell its H. pylori stool antigen test for use on DiaSorin's Liaison platform. The firms will also end pending legal disputes.